Lupus is a chronic autoimmune disease wherein the body’s immune system fails to recognize its cells and tissues as self and starts attacking them. The four major types of lupus include systemic lupus erythematosus (SLE), cutaneous lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus. Systemic lupus erythematosus is the most common type of lupus that causes damage to several organs throughout the body such as the kidney, lungs, heart, and others. Systemic lupus erythematosus causes inflammation in the skin, joints, lungs, blood cells, kidneys, etc. This condition usually goes through cycles of flare-ups (symptoms appear) and remissions (symptoms disappear). In discoid lupus erythematosus (a type of cutaneous lupus erythematosus), the symptoms affect only the skin, thus causing circular lesions on areas such as scalp, face, etc. These lesions may become thick and scaly and in some cases, lead to scarring and skin discoloration. Drug-induced lupus erythematosus may be caused due to medication such as hydralazine, procainamide, isoniazid, etc. The symptoms of drug-induced lupus erythematosus are similar to SLE but are often less severe. Neonatal lupus is an autoimmune condition that occurs when a mother passes on an antibody (anti-Ro/SSA antibody, anti-La/SSB antibody, etc.) to the infant through placenta. These antibodies may cause symptoms such as skin rash, low blood counts, congenital heart defect, and others at birth.
The global lupus therapeutic market is estimated to be valued at US$ 2,795.2 million in 2022 and is expected to exhibit a CAGR of 8.6% over the forecast period (2022-2030).
Figure 1. Global Lupus Therapeutic Market Share (%), By Region, 2022
The increasing research and development activities for the development of novel therapeutics for the treatment of lupus is expected to drive the market growth over the forecast period.
For instance, in November 2021, AstraZeneca, a U.K. based biopharmaceutical company announced positive results from its TULIP Phase 3 clinical trial program (focused on determining the efficacy and safety of Anifrolumab), stating that Saphnelo (anifrolumab) - a human monoclonal antibody showed greater reduction of SLE when used in combination with standard therapy than the use of only standard therapy.
|Base Year:||2021||Market Size in 2022:||US$ 2,795.2 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||8.6%||2030 Value Projection:||US$ 5,408.1 Mn|
Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh
|Restraints & Challenges:||
Figure 2. Global Lupus Therapeutic Market Value (US$ Mn), By Disease Type, 2022
Key players operating in the market are focusing on submitting applications for the approval of novel drugs to be used in the treatment of lupus, which is expected to drive growth of the global lupus therapeutic market over the forecast period.
For instance, in December 2020, GlaxoSmithKline plc, a U.K. based pharmaceutical company announced that it has received the U.S. Food and Drug Administration (FDA) approval for its drug BENLYSTA (belimumab) to be used in combination with standard therapy for treatment of adult patients with active lupus nephritis (LN), a kidney disease caused due to SLE.
Global Lupus Therapeutic Market – Impact of Coronavirus (Covid-19) Pandemic
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was first reported from Wuhan, China in December 2019, and was declared as a global pandemic by the World Health Organization (WHO), which designates this SARS-CoV-2 infection as novel Coronavirus (COVID-19). According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread across the globe infecting over 409 million population leading to more than 5.8 million deaths as of February 13, 2022. The negative impact of COVID-19 on the healthcare domain is huge and it has significantly disrupted the healthcare industries’ entire supply chain, from raw materials to manufacturing and delivery. Similarly, the COVID-19 pandemic is expected to show a positive impact on the overall growth of the lupus therapeutics market owing to the association of COVID-19 with lupus.
For instance, according to an article published by the Journal of Medical Case Reports in January 2021, association between COVID-19 and lupus is not yet determined but it suggests that COVID-19 could be a potential agent which is responsible for producing autoantibodies and causing systemic lupus erythematosus. The same source also discusses a case report of a 39 year old male in Iran who has been the first case of SLE manifestation following COVID-19.
Global Lupus Therapeutic Market - Restraint
The side effects of drugs used for treatment of lupus is one of the major factors that are expected to hinder growth of the global lupus therapeutic market over the forecast period. For instance, according to an article published by the Lupus Science and Medicine journal (a peer-reviewed, open access journal) in March 2018, nearly all patients undergoing treatment for SLE report one or more adverse events such as nausea, vomiting, bone toxicity, and others.
Major players operating in the global lupus therapeutic market include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
Lupus is an autoimmune disorder wherein the immune system of the body attacks body’s own healthy tissues and organs, resulting in swelling, tissue damage, and pain. The inflammation caused by lupus can affect the joints, kidneys, brain, blood cells, skin, heart, and lungs. The exact cause of lupus is unknown, however, certain risk factors are associated with lupus. These risk factors include hormones, genetics, smoking, viral infection, and others. Some of the common symptoms related to lupus include fatigue, muscle and joint pain, fever, mouth ulcers, headaches, arthritis, malar rash, unusual hair loss, and others. Diagnosis of lupus is difficult as its symptoms mimic those of other ailments such as rheumatoid arthritis, scleroderma, etc. However, a butterfly-shaped rash, also known as malar rash across the nose and cheek is a highly distinctive feature of lupus. There are other complications that can arise from lupus, such as urinary tract infections, yeast infections, herpes, pregnancy loss, bone tissue death, and others.
The high prevalence and incidence of lupus, rapid research and development activities towards development of novel therapeutics for treatment of lupus, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global lupus therapeutic market over the forecast period.
For instance, according to an article published by the Lupus Science and Medicine journal, in April 2021, it is estimated that the incidence and prevalence of Systemic Lupus Erythematosus (SLE) were around 0.3 to 5.1 per 100 000 per year and 6.5 to 85 per 100 000 population, respectively in Europe in 2020.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.